췌장암의 최신치료 = Recent treatment of pancreatic cancer

다국어 초록 (Multilingual Abstract)

Pancreatic cancer has a high mortality rate and short survival as a result of the high incidence of metastatic disease at diagnosis, the fatal clinical course, and the lack of successful therapeutic strategies. Gemcitabine remains the only standard of care for this disease. Increasing combination therapies containing gemcitabine have been tested or are undergoing investigation. In the last decade, despite a number of clinical trials assessing novel cytotoxic agents and cell signaling inhibitors, the overall survival has reached a plateau that remains difficult to improve on. This review presents recent developments involving newer chemotherapeutic and molecular targeted agents, and identifies efforts for individualized treatment strategies. (Korean J Med 77:695-702, 2009)

참고문헌 (Reference)

1 Burris HA 3rd, "in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial" 15 : 2403-2413, 1997

2 Moertel CG, "Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group" 48 : 1705-1710, 1981

3 Fazal S, "Supportive and palliative care of pancreatic cancer" 8 : 240-253, 2007

4 Gebbia V, "Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice" 18 (18): vi124-vi127, 2007

5 Sohail MA, "Role of anticoagulation in the management of pancreatic cancer" 10 : 82-87, 2009

6 Riess H, "Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)" 8 : 361-, 2008

7 Heinemann V, "Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer" 24 : 3946-3952, 2006

8 Tempero M, "Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma" 21 : 3402-3408, 2003

9 Berlin JD, "Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297" 20 : 3270-3275, 2002

10 Saif MW, "Pancreatic cancer: are we moving forward yet?" JOP 166-176, 2007

11 Kalser MH, "Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection" 120 : 899-903, 1985

12 Ferrone CR, "Pancreatic adenocarcinoma: the actual 5-year survivors" 12 : 701-706, 2008

13 Kang SP, "Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients: can we establish standard of care with available data?" 9 : 83-90, 2008

14 Saif MW, "New developments in the treatment of pancreatic cancer" JOP 391-397, 2008

15 Triano LR, "New developments in the treatment of locally advanced pancreatic cancer" JOP 366-372, 2009

16 Saif MW, "Is there a standard of care for the management of advanced pancreatic cancer?" JOP 91-98, 2008

17 Herrmann R, "Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group" 25 : 2212-2217, 2007

18 Small W Jr, "Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial" 26 : 942-947, 2008

19 Taieb J, "FOLFIRI 3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study" 18 : 498-503, 2007

20 Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group" 25 : 1960-1966, 2007

21 Sun S, "Endoscopic ultrasound- guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial" 38 : 399-403, 2006

22 Chang KJ, "Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer" 5 : 107-111, 2008

23 Jin Z, "Endoscopic ultra sonography-guided interstitial implantation of iodine 125-seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma: a prospective pilot study" 40 : 314-320, 2008

24 Chari ST, "Detecting early pancreatic cancer: problems andprospects" 34 : 284-294, 2007

25 Moertel CG, "Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer" 2 : 865-867, 1969

26 Katz MH, "Borderline resectable pancreatic cancer: the importance of this emerging stage of disease" 206 : 833-846, 2008

27 Varadhachary GR, "Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy" 13 : 1035-1046, 2006

28 Li J, "Any progress in the management of advanced pancreatic cancer?" JOP 361-365, 2009

29 Li J, "Advancements in the management of pancreatic cancer" 10 : 109-117, 2009

30 Saif MW, "Adjuvant treatment of pancreatic cancer in 2009: where are we?" JOP 373-377, 2009

31 Klinkenbijl JH, "Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group" 230 : 776-782, 1999

32 Oettle H, "Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial" 297 : 267-277, 2007

33 Neoptolemos JP, "A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer" 350 : 1200-1210, 2004

34 Cohen SJ, "A randomized phase III study of radiotherapyalone or with 5-fluorouracil and mitomycin-C in patientswith locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282" 62 : 1345-1350, 2005

35 Hecht JR, "A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma" 9 : 555-561, 2003

36 Ganly I, "A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer" 6 : 798-806, 2000